Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of ACT-541468 in Healthy Japanese and Caucasian Subjects
NCT03101189Phase 1Completed
- Sponsor
- Idorsia
- Start
- Mar 2017
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of daridorexant in Insomnia (3 arms), sponsored by Idorsia. Primary endpoints: Maximum plasma concentration at Day 5 and Area under the plasma concentration-time curve during a dosing interval at Day 5. Started Mar 2017; status: completed.
02
Drugs
daridorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT03101189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101189.